Skyphos achieves two-second production cycle for microneedle patches using volumetric additive lithography.

Skyphos achieves two-second production cycle for microneedle patches using volumetric additive lithography.

Skyphos, based in Italy, has successfully demonstrated the use of volumetric 3D printing to manufacture medical-grade microneedle patches in under two seconds. This process utilizes additive lithography, a light-based technique that solidifies entire 3D volumes simultaneously rather than layer-by-layer, significantly increasing throughput for high-density diagnostic and therapeutic structures. The company focuses on optimizing the geometry of these arrays to ensure precise drug delivery and diagnostic accuracy while maintaining the structural integrity of the polymer materials used in medical applications.

Volumetric printing addresses the primary bottleneck in micro-scale additive manufacturing, which is the slow build speed inherent in traditional point-scanning or layer-based DLP and SLA systems. While competitors in the micro-AM space often rely on two-photon polymerization or high-resolution projection systems that require extended build times for dense arrays, the volumetric approach offers a path toward mass-market scalability for disposable medical devices. This technology positions Skyphos within the high-volume medical manufacturing value chain, specifically targeting the transition from prototyping to industrial-scale production of personalized transdermal patches.

For medical device manufacturers, the transition from batch processing to high-speed volumetric production requires rigorous validation of material biocompatibility and mechanical consistency across rapid build cycles. Skyphos must now demonstrate that its two-second process can maintain the strict tolerances required for pharmaceutical regulatory approval in clinical settings. Buyers should prioritize evaluating the surface finish and material purity of these patches compared to traditional injection-molded or micro-machined alternatives.